Artal Group S.A. Avrobio, Inc. Transaction History

Artal Group S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	SELL	$13.05 - $21.88 $306,009 - $513,064	-23,449 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$14.12 - $23.44 $939,700 - $1.56 Million	-66,551 Reduced 73.95%	23,449 $331,000
Q2 2019 Aug 09, 2019	SELL	$13.21 - $27.29 $132,100 - $272,900	-10,000 Reduced 10.0%	90,000 $1.46 Million
Q3 2018 Nov 09, 2018	SELL	$26.95 - $52.7 $673,750 - $1.32 Million	-25,000 Reduced 20.0%	100,000 $5.19 Million
Q2 2018 Aug 10, 2018	BUY	$28.08 - $31.2 $3.51 Million - $3.9 Million	125,000 New	125,000 $3.57 Million

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.